SPM 5185
Latest Information Update: 20 May 1996
Price :
$50 *
At a glance
- Originator Schwarz Pharma
- Developer Thomas Jefferson University
- Class Anti-ischaemics; Antiplatelets; Heart failure therapies; Organic nitrates; Vasodilators
- Mechanism of Action Nitric oxide stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Myocardial ischaemia